Tech Company Financing Transactions
Nuclera Funding Round
Private investors and Verve Capital participated in a $15.5 million Series B funding round for Nuclera. The funding round closed on 7/6/2022.
Transaction Overview
Company Name
Announced On
7/6/2022
Transaction Type
Venture Equity
Amount
$15,500,000
Round
Series B
Investors
private investors (Jonathan Milner)
Proceeds Purpose
The Series B raise will let us quickly scale all functions from R&D through to our commercial team. It will allow us to make proteins accessible and continue on our journey to deliver a game-changing technology to the market.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
137 Cambridge Science Park Milton Rd.
Cambridge, CB4 0GD
UK
Cambridge, CB4 0GD
UK
Phone
Undisclosed
Website
Email Address
Overview
Nuclera is a Bioprinter company that enables life science researchers to accelerate breakthrough improvements in human health through easy access of biomolecules.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Chen
Chief Financial Officer
Jiahao Huang
Chief Technical Officer
Gordon McInroy
Vice President
Colin Barnes
Vice President
Eugene Bragin
VP - Bus. Development
George Easow
VP - Human Resources
Charu Maini
VP - Marketing
Kristine Friscino
VP - R & D
Tobias Ost
VP - R & D
Rick Paolini
Browse more venture capital transactions:
Prev: 7/6/2022: Adapty venture capital transaction
Next: 7/6/2022: Thabor Therapeutics venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs